| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6175080 | European Urology | 2016 | 7 Pages |
Abstract
Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies. We compared 24-mo recurrence-free survival (RFS) with chemohyperthermia (CHT) versus bacillus Calmette-Guérin (BCG) therapy. According to these data, CHT therapy appears to be safe and has higher 24-mo RFS than BCG therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, Ottavio de Cobelli, Giorgio Canepa, Fabrizio Verweij, Boaz Moskovitz, Antoine G. van der Heijden, J. Alfred Witjes,